



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|--|
| (51) International Patent Classification 5 : A61K 37/00, 37/04, C07K 15/28 C12N 1/00, 15/13, 15/19 C12N 15/10, 15/63 | A1 | (11) International Publication Number: WO 94/08601 (43) International Publication Date: 28 April 1994 (28.04.94) |
| (21) International Application Number: PCT/US93/09895 (22) International Filing Date: 14 October 1993 (14.10.93) (30) Priority data: 07/961,788 14 October 1992 (14.10.92) US (60) Parent Application or Grant (63) Related by Continuation US 07/961,788 (CIP) Filed on 14 October 1992 (14.10.92) (71) Applicant (for all designated States except US): THE BOARD OF TRUSTEES OF THE LELAND STAN- FORD JUNIOR UNIVERSITY [US/US]; 857 Serra Street, Stanford, CA 94305-6225 (US). | | (72) Inventors; and (75) Inventors/Applicants (for US only) : LEVY, Ronald [US/ US]; 415 Olive Street, Menlo Park, CA 94025 (US). TAO, Mi-Hua [TW/US]; 966 Mears Court, Stanford, CA 94305 (US). (74) Agents: PARK, Freddie, K. et al.; Morrison & Foerster, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). (81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> |
| (54) Title: ENHANCEMENT OF B CELL LYMPHOMA TUMOR RESISTANCE USING IDIOTYPE/CYTOKINE CON- JUGATES (57) Abstract Immunocomplexes which consist essentially of a B cell lymphoma tumor-associated antigen or a fragment thereof contain- ing an epitope characteristic of the tumor and an immune-enhancing cytokine such as GM-CSF, IL-2 or IL-4 elicit immune re- sponses which are protective with respect to tumor proliferation. Antibodies immunoreactive with these immunocomplexes are al- so useful as passive vaccines and as analytical tools. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AT | Austria | FR | France | MR | Mauritania |
| AU | Australia | GA | Gabon | MW | Malawi |
| BB | Barbados | GB | United Kingdom | NE | Niger |
| BE | Belgium | GN | Guinea | NL | Netherlands |
| BF | Burkina Faso | GR | Greece | NO | Norway |
| BG | Bulgaria | HU | Hungary | NZ | New Zealand |
| BJ | Benin | IE | Ireland | PL | Poland |
| BR | Brazil | IT | Italy | PT | Portugal |
| BY | Belarus | JP | Japan | RO | Romania |
| CA | Canada | KP | Democratic People's Republic of Korea | RU | Russian Federation |
| CF | Central African Republic | KR | Republic of Korea | SD | Sudan |
| CG | Congo | KZ | Kazakhstan | SE | Sweden |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovak Republic |
| CM | Cameroon | LU | Luxembourg | SN | Senegal |
| CN | China | LV | Latvia | TD | Chad |
| CS | Czechoslovakia | MC | Monaco | TG | Togo |
| CZ | Czech Republic | MG | Madagascar | UA | Ukraine |
| DE | Germany | ML | Mali | US | United States of America |
| DK | Denmark | MN | Mongolia | UZ | Uzbekistan |
| ES | Spain | | | VN | Viet Nam |
| FI | Finland | | | | |

-1-

5 ENHANCEMENT OF B CELL LYMPHOMA TUMOR RESISTANCE
 USING IDIOTYPE/CYTOKINE CONJUGATES

Technical Field

10 The invention relates to the field of
modulating B cell lymphoma tumor growth using
immunological methods. More specifically, the invention
concerns use of immunological constructs to confer
resistance to B cell lymphoma tumors, and to enhance
15 immune response.

Background Art

 Malignant tumors often express characteristic
antigens or "markers" which offer a mechanism for tumor
20 prevention, resistance or treatment. The antigens which
are characteristic of the tumor may be purified and
formulated into vaccines. This may stimulate an antibody
response and a cellular immune response which are helpful
in controlling tumor growth. At a minimum, the
25 antibodies raised by these antigens can be used as
detection tools to monitor the level of tumor marker in
the host to track the course of the disease or the
effectiveness of treatment.

 It is well known that the immunogenicity of
30 antigens can be enhanced by coupling these hapten-bearing
moieties to carriers. A variety of carriers are
routinely used, such as keyhole limpet hemocyanin and
various serum albumins. It is also understood that
certain cytokines, such as GM-CSF, have the capacity to
35

-2-

enhance primary antibody responses to antigens
(Morrissey, P.J., et al, J Immunol (1987) 139:1113-1119).

The immune response-enhancing ability of a
cytokine, when coupled to a viral antigen, has been shown
5 by Hinuma, S., et al, FEBS (1991) 288:138-142. In this
work, interleukin-2 was coupled to a herpes simplex virus
type I glycoprotein by generating a fusion protein
consisting of the glycoprotein D and human IL-2. The
conjugate was shown to induce high antibody responses and
10 cell-mediated immunity to HSV-I in mice.

It has now been found that B cell lymphoma
tumor-associated antigens can be coupled to immune
response-enhancing cytokines, such as GM-CSF, IL-2 and
IL-4, to produce an immune response to the tumor antigen
15 and enhance the ability of the host to resist tumor
growth associated with the antigen.

Disclosure of the Invention

The invention provides compositions and methods
20 for the modulation of B cell lymphoma tumor growth where
the tumor is characterized by an associated antigen
carrying an epitope which is characteristic of the tumor.
The immunogenicity of preparations of the antigen used to
raise antibodies and stimulate an immune response can be
25 enhanced by coupling the antigen to an appropriate
cytokine. The conjugate is superior in effect to the
antigen coupled to conventional immunogenic carriers.

In one aspect, the invention is directed to an
immunocomplex, which complex comprises a B cell lymphoma
30 tumor-associated antigen covalently coupled to an immune
-enhancing cytokine. The complex may be obtained by
generating the antigen and the cytokine as a fusion
protein using recombinant techniques; thus, in another
aspect, the invention is directed to recombinant
35 materials and methods for production of such fusion

-3-

proteins. In still other aspects, the invention is directed to pharmaceutical compositions and vaccines containing the immunogenic complexes of the invention and to methods of conferring antitumor immunity using these
5 complexes. In still other aspects, the invention is directed to antibodies generated by immunization with the complexes of the invention and to antibodies immunospecific to the conjugates. The invention is also directed to methods to confer immunity by administering
10 polyclonal or monoclonal preparations of antibodies generated by the conjugates.

It has also been found that the immune-enhancing cytokine activity is improved by extending or coupling the cytokine to an additional moiety.
15 Accordingly, in another aspect, the invention is directed to enhancing the activity of a cytokine by coupling to an additional moiety.

Brief Description of the Drawings

20 Figure 1A shows diagrammatically the construction of expression vectors for a B cell lymphoma tumor antigen Ig heavy chain coupled to murine GM-CSF; Figure 1B shows diagrammatically the construction of an expression vector for the light chain of this tumor-associated antigen.
25

Figure 2 shows diagrammatically the products of transformed mouse myeloma cells transfected with the vectors illustrated in Figures 1A and 1B.

Figure 3 is a graph showing the ability of
30 GM-CSF-coupled antigen to support the proliferation of a GM-CSF-dependent cell line.

Figure 4 is a graph which shows the ability of antibodies produced against GM-CSF to inhibit the proliferative activity of the immunocomplex.
35

-4-

Figure 5 is a graph showing the ability of mice immunized with the immunocomplex of the invention to resist tumor challenge.

Figure 6A shows the dimeric Id/interleukin fusion proteins.

Figure 6B is a photocopy of a photograph of the chimeric tumor idiotype/interleukin proteins analyzed by gel electrophoresis.

Figure 6C is a photocopy of a photograph of the immunoblotting analysis of the chimeric idiotype/interleukin proteins.

Figure 7A shows the results of an analysis of the purified chimeric idiotype/interleukin proteins for their ability to support the proliferation of a murine IL-2/IL-4-responsive T cell line, HT-2.

Figure 7B is a comparison of the activity of recombinant IL-4, the idiotype/IL-4 chimeric protein and the idiotype antigen in the proliferation assay described above.

Figures 7C and 7D show that the activity of Id/MoIL-2 and Id/MoIL-4 was inhibited by anti-IL-2 and anti-IL-4 antibodies, respectively, but not by a control antibody.

Figure 8A illustrates that mice vaccinated intraperitoneally with Id/MoIL-2 or Id/MoIL-4 had a significantly prolonged survival time compared with mice receiving Id alone.

Figure 8B illustrates that mice immunized with Id/MoIL-2 and Id/MoIL-4 also induced protective immunity and resulted in 40% and 30% long-term survivors, respectively, while vaccination with a mixture of Id and IL-2 or IL-4 yielded no protection.

-5-

Modes of Carrying Out the Invention

The invention provides B cell lymphoma antitumor vaccines of enhanced immunogenicity wherein the active ingredient is an immunocomplex containing an
5 immune-enhancing cytokine covalently bound to a B cell lymphoma tumor-associated antigen or a fragment thereof containing at least one epitope characteristic of the tumor.

By "tumor-associated antigen" is meant a
10 proteinaceous molecule containing at least one epitope wherein the epitope characterizes the tumor and is unique to the tumor as opposed to other tissues. The nature of the tumor-associated antigen will, of course, vary with the nature of the tumor. For B-cell lymphomas, the
15 tumor-associated antigen is most frequently an immunoglobulin. The use of such tumor-associated antigens to produce monoclonal anti-idiotypic antibodies has been described in U.S. Patent 4,661,586 and U.S. Patent 4,816,249. An assay for the monoclonal antibodies
20 against tumor surface immunoglobulins is described and claimed in U.S. Patent 4,513,088. The disclosure of these patents is incorporated herein by reference.

By "immune-enhancing cytokine" is meant a cytokine that is capable of enhancing the immune response
25 when the cytokine is generated *in situ* or is administered to a mammalian host. Such cytokines are well known in the art and have become numerous. They include GM-CSF, IL-2, IL-3, and IL-4.

The immune-enhancing activity of cytokines can
30 also be improved by their extension with additional moieties. As shown in Example 2, a cytokine coupled to an additional molecular structure is more effective in stimulating proliferation of NFS-60 cells than the cytokine alone. Such additional molecular structure is

35

-6-

variable, and may comprise additional copies of the cytokine itself.

The tumor-associated antigen or the relevant epitope-bearing portion thereof may be coupled to the immune-enhancing cytokine using conventional coupling techniques such as coupling with dehydrating agents such as ECDI, dicyclohexylcarbodiimide (DCCI), and the like. In addition, commercially available or other synthetic linkers may be used in standard chemical coupling techniques. Such linkers, which are capable of coupling through sulfhydryl groups, amino groups, or carboxyl groups, are available from Pierce Chemical Co. (Rockford, IL). If the tumor-associated antigen or cytokine contains glycosylation, coupling can also be effected through the carbohydrate moieties using, for example, reductive amination. A wide variety of standard coupling techniques for covalent binding of the B cell lymphoma tumor-associated antigen with the cytokine is known in the art.

The B cell lymphoma tumor-associated antigen may be obtained by purification from the tumor or may be synthesized using recombinant techniques. In the case of the B-lymphomas, the immunoglobulin antigen may be affinity purified using, for example, protein A or other suitable means. A wide variety of cytokines is available in the art, and the genes for many of the cytokines have been cloned so that recombinant production of the cytokine portion of the complex may also be effected.

Alternatively, the immunocomplex can be constructed recombinantly as a fusion protein using the genes encoding the B cell lymphoma tumor-associated antigen and the immune-enhancing cytokine. Such fusions can be constructed by ligating DNAs encoding each protein in reading frame and coupling these to standard expression systems, as is by now generally known in the

-7-

art. In general, it is preferred to produce the fusion proteins in mammalian host cells, although procaryotic or yeast expression is also feasible. The choice of control sequences that will be operably linked to the DNA
5 encoding the fusion protein will depend on host choice, and the wide availability of control sequences for selected hosts is by now well known.

The immunocomplexes of the invention can then be used to engender an immune response in the host to be
10 protected against the tumor. Generally, the immunocomplex is administered by injection -- intravenous, intramuscular, intraperitoneal and the like -- along with a suitable vehicle and excipient for injection. Suitable formulations for injection,
15 including appropriate adjuvants, can be found, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, latest edition. Protocols for administration can be formulated using routine optimization techniques, whereby repeated
20 administration and concomitant antibody titering of the serum is performed until suitable titers are obtained. The polyclonal antisera produced by administration of the immunocomplexes of the invention can also be used for passive immunization of hosts against tumor
25 proliferation. Preferably, however, the antibody-producing cells of the immunized host are immortalized, for example, using the standard fusion techniques of Kohler and Milstein, and the resulting immortalized cells are screened for production of antibodies which are
30 immunoreactive with the B cell lymphoma tumor-associated antigen.

By "immunoreactive with the B cell lymphoma tumor-associated antigen" is meant that the antibodies have sufficiently high affinity for such antigens to
35 detect them in standard assay systems. Such polyclonal

-8-

or monoclonal antibodies are also useful in passive immunization.

Antibodies will also be produced which are immunospecific for the immunocomplexes. By

5 "immunospecific for the immunocomplex" is meant that the antibodies recognize the immunocomplex as distinct from the components thereof. These immunospecific antibodies are useful in monitoring the levels of immunocomplex circulating in the plasma as well as in monitoring the

10 production of the immunocomplex by expression of the appropriate recombinant systems. These antibodies may also be conveniently used for purification of the immunocomplex from the production vessels.

15 The following examples are intended to illustrate but not to limit the invention.

Example 1

Construction of Idiotypic/GM-CSF Fusion Protein

20 A carcinogen-induced murine B-cell tumor, 38C13, was used as the source of tumor-derived idiotypic protein. Immunoglobulins produced by this tumor, 38CId, have been used in immunization protocols and shown to be effective in protecting animals from subsequent lethal

25 tumor challenge. In these immunizations, the antigen was coupled to standard immunogenic carriers such as KLH.

The V_H and V_L genes of the 38C13 tumor cells were cloned using the polymerase chain reaction (PCR) and ligated to human $Ig\gamma$ and $Ig\kappa$ constant region genes in the

30 heavy- and light-chain expression vectors pSV2- Δ HGPT and pSV184- Δ Hneo, respectively. The murine GM-CSF gene was cloned by PCR and ligated to the C γ 3 exon of the heavy-chain gene. The construction of these vectors is shown diagrammatically in Figure 1A and 1B, respectively.

35 Figure 1A shows diagrammatically the coupling of the V_H

-9-

region of 38C13 and the C γ 1, H, C γ 2, and C γ 3 regions of human IgG. The heavy-chain DNA is constructed including or not including the coding sequence for murine GM-CSF. The constructs are then inserted into the host vector as shown.

Figure 1B shows the coupling of the murine V κ 38C13 with the human C κ constant region. The hybrid gene is ligated into pSV184- Δ Hneo under control of the host vector promoter.

Both plasmids are then transfected by electroporation into the Ig-deficient murine plasmacytoma cell line AG8.653 for expression. The culture supernatants were screened for production of the chimeric proteins using a standard ELISA assay, and the chimeric proteins were purified by protein-A chromatography.

Figure 2 shows diagrammatically the proteins produced. TF38CId is the tumor-associated antigen comprising the tumor idiotype coupled with constant regions derived from human immunoglobulins. TF38CId/MoGM-CSF is identical, except for the fusion to murine GM-CSF. The chimeric proteins secreted by the murine myeloma cells were analyzed by reducing and nonreducing SDS-PAGE. Analysis of the results showed that TF38CId/MoGM-CSF was expressed as a molecule with a molecular weight of 210 kd.

Example 2

Ability of the Fusion Protein to Retain

Immune Enhancement

Proliferation assays were conducted by plating GM-CSF-dependent NFS-60 cells with various concentrations of test compound. The cells were incubated for 18 hours and the proliferation determined by standard labeled thymidine-incorporation assay.

-10-

Figure 3 shows the results of this assay. The graph in Figure 3 plots thymidine incorporation in counts per minute (Y-axis) against the concentration in pM (X-axis). Treatment with TF38CId alone (\square) provides no stimulation of proliferation; treatment with recombinant murine GM-CSF alone (O) shows intermediate ability to proliferate; treatment with the fusion protein of the invention, TF38-CId/MoGM-CSF (\bullet) shows greatly enhanced ability to stimulate proliferation in a dose-dependent fashion.

The ability of the fusion protein to stimulate cell proliferation could, as expected, be inhibited by antibodies raised against GM-CSF and, to a lesser extent, by antibodies raised against the constant heavy chain to which the GM-CSF is fused. In this assay, NFS-60 cells were incubated with 250 pM of the fusion protein and with various antibodies. The proliferation was determined by thymidine uptake, as above.

Figure 4 shows the results of these assays where antibody concentration in ng/ml is plotted on the X-axis against thymidine incorporated on the Y-axis. As shown, neither antibodies to human constant κ -chain (\blacksquare) or to normal rat immunoglobulin (O) were able to inhibit the proliferation of NFS-60 cells stimulated by the fusion protein of the invention. However, proliferation was almost completely inhibited by 78 ng/ml rat anti-GM-CSF (\bullet) and, to a lesser extent, by goat antihuman Ig- γ (\square) wherein 625 ng/ml of these antibodies diminished proliferation almost to zero.

30

Example 3

Ability of the Fusion Protein to Immunize Mice

Groups of C3H/HeN mice were immunized twice intraperitoneally with either KLH-conjugated TF38CId, unconjugated TF38CId, TF38CId mixed with recombinant

35

-11-

murine GM-CSF, or with the fusion protein of the invention, TF38CId/MoGM-CSF. The immunogens were administered at days -28 and -14 before tumor challenge at day 0. The animals were bled at days -18 and -4 and anti-idiotypic antibodies determined by ELISA against native 38CId (mouse IgM, κ). The antibody titers are shown in Table 1.

Table 1

| 10 | IMMUNOGEN | ANTI-ID ($\mu\text{g/ml} \pm \text{SD}$) | ANTI-ID ($\mu\text{g/ml} \pm \text{SD}$) |
|----|-----------------------------|--|--|
| | | DAY (-18) | DAY (-4) |
| | KLH-conjugated | 23 \pm 14 | 296 \pm 207 |
| | TF38CId | | |
| | TF38CId | 0 | 0 |
| 15 | TF38CId & rMOGM-CSF Mixture | 0 | 0 |
| | TF38CId/MoGM-CSF | 55 \pm 39 | 152 \pm 139 |

As seen in the table, both the KLH-conjugated idio-
 20 type and the protein of the invention raised substantial antibody titers; the KLH-conjugated complex was slightly more effective.

However, the fusion protein was more successful in prolonging survival after challenge with tumor cells.
 25 At day 0, the mice were challenged with 38C13 tumor cells intraperitoneally, and the survival of the challenged mice was followed. The results are shown in Figure 5.

Mice immunized with idio-
 type alone (TF38CId) or with idio-
 type mixed with recombinant GM-CSF (● and □,
 30 respectively) survived only 20-25 days after challenge. All animals were dead after that time. Animals immunized with KLH-conjugated idio-
 type (○) had a 50% survival rate at day 25 and 30% of the animals were still alive after 50 days. Mice immunized with 10 μg of fusion protein (●)
 35 had a 50% survival rate after 34 days and 40% were still

-12-

alive at day 50. Mice immunized with 50 μ g of the fusion protein (Δ) had a 60% survival rate at day 50.

Example 4

5 Construction of Idiotypic/IL-2 and IL-4 Fusion Proteins

To make Id/MoIL-2 and Id/MoIL-4 fusion proteins, the genetic fragment encoding mature murine IL-2 or IL-4 was attached to the end of the C_H3 exon of the human C γ 1 gene. The resulting fusion proteins were
10 dimeric with respect to the interleukin molecule as shown in Fig. 6A. All proteins were produced in tissue culture and purified by protein A chromatography. These chimeric tumor idiotypic proteins were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
15 immunoblotting techniques. Under reducing conditions the protein bands of Id migrate with apparent mw of 30.5- and 58-kD, representing the heavy and light chains, respectively (Fig. 1B). Reduction of Id/MoIL-2 and Id/MoIL-4 also gave a 30.5-kD light chain, but both heavy
20 chain molecules migrated slower than Id heavy chain with apparent mw of 76- and 72-kD, respectively, indicating that they contained the IL-2 or IL-4 tail. As shown in the nonreducing gel (Fig. 6B), the Id protein was secreted as a single band of mw of 160-kD. Both fusion
25 proteins were migrated as doublets in the nonreducing gel with apparent mw of 191- and 198-kD (Id/MoIL-2) and 181- and 191-kD (Id/MoIL-4), indicating that these molecules are present in two different conformations. The immunoblotting analysis of these chimeric idiotypic
30 proteins is shown in Fig. 6C. The results were consistent with the expected constructs of these proteins, in that the anti-Id antibody recognizes all three Id-derived molecules; in contrast, anti-IL-2 and anti-IL-4 antibodies only recognize Id/MoIL-2 and
35 Id/MoIL-4 fusion molecules, respectively.

-13-

Example 5Ability of the IL Fusion Proteins to Retain
Immune Enhancement

ELISA assay results showed that Id, Id/MoIL-2,
5 and Id/MoIL-4 all reacted with four different monoclonal
anti-idiotypic antibodies raised against the native
murine 38C13 idiotypic protein. To determine the
functional activity of the murine IL-2 or IL-4 portion of
the fusion molecules, purified proteins were analyzed for
10 their ability to support the proliferation of a murine
IL-2/IL-4-responsive T cell line, HT-2. While Id was
completely negative in this assay, Id/MoIL-2 clearly
demonstrated the ability to stimulate the growth of HT-2
cells in a dose-dependent manner (Fig. 7A). On a per
15 molecule basis, Id/MoIL-2 was indistinguishable from
recombinant murine IL-2 in the ability to induce the
proliferation of HT-2 cells. When compared to
recombinant IL-4, Id/MoIL-4 fusion protein had about a
25-fold decrease in the activity (Fig. 7B). The
20 reduction in specific activities is not explained by the
low pH used for eluting Id fusion proteins from protein A
Sepharese, since the activity of the Id/MoIL-4 from the
transfected cell culture media and the purified protein
is almost identical. Mouse IL-4 contains three sets of
25 disulfide bonds which are important for maintaining its
structure and the biological activities. Fusion of IL-4
to the immunoglobulin heavy chain may disrupt the normal
disulfide pairings and thus decrease its activity. The
fact that two conformational Id/MoIL-4 molecules are
30 present in the purified proteins supports this
hypothesis. Fig. 7C and 7D show that the activity of
Id/MoIL-2 and Id/MoIL-4 was inhibited by anti-IL-2 and
anti-IL-4, respectively, but not by a control antibody,
indicating that the cytokine activity is specific.
35 Incubation of the Id/MoIL-2 or Id/MoIL-4 with antibody

-14-

against human γ -chain also arrested cell growth, indicating that the cytokine activity is in the form of a fusion molecule.

5

Example 6Ability of the IL Fusion Proteins to Immunize Mice

Anti-idiotypic antibodies were induced by immunization with different idiotypic proteins. Groups of eight- to ten-week-old female C3H/HeN mice were immunized intraperitoneally or subcutaneously with the indicated immunogens in phosphate-buffered saline unless otherwise indicated. Ten mice were included in each group. Two weeks later mice were boosted with the same antigens. KLH-Id was made by coupling KLH to Id using 0.1% glutaraldehyde#. The cytokine molarity of 1.4 μ g of recombinant murine IL-2 (rMoIL-2) and 1.9 μ g of rMoIL-4 was equivalent to 10 μ g of Id/MoIL-2 and Id/MoIL-4, respectively. Serum was sampled by tail bleeding ten days after the last immunization. The titers of antisera against native 38C13 idio type (IgM, κ) were determined by ELISA using a cocktail of murine antibodies [S3H5 (IgG1), S1C5 (IgG2a), S5A8 (IgG2b)] as a standard. The results are shown in Table 2. The data are expressed as the mean concentration \pm standard deviation (SD).

25

30

35

-15-

Table 2

| | Immunogen | Dose (μ g) | Anti-idiotypic antibody (μ g/ml \pm SD) | |
|----|--------------|-----------------|---|------------------|
| | | | Intraperit. | Subcutan. |
| 5 | Id | 10 | 0 | 0 |
| | Id+rMoIL-2 | 10 + 1.4 | 0 | 0 |
| | Id+rMoIL-4 | 10 + 1.9 | 0 | 0 |
| | KLH-Id+adj.* | 10 | 205.7 \pm 39.0 | 139.8 \pm 19.0 |
| 10 | Id/MoIL-2 | 10 | 18.3 \pm 10.4 | 28.7 \pm 16.2 |
| | Id/MoIL-4 | 10 | 79.0 \pm 25.6 | 45.1 \pm 15.9 |

*KLH-Id was administered with the adjuvant SAF-1 in the first immunization and with incomplete SAF-1 (lacking the MDP component) in the second immunization.

Sera from animals immunized with Id and its cytokine-derived fusion proteins, either intraperitoneally or subcutaneously, were collected 10 days after the second immunization and analyzed in an ELISA for their reactivity with native 38C13 idiotype protein. Id did not induce detectable anti-idiotypic antibodies (Table 2); thus the carrier or helper effects of human immunoglobulin constant regions were negligible. Conversely, both Id/MoIL-2 and Id/MoIL-4 induced significant amounts of anti-idiotypic antibodies in all immunized animals. Vaccination of Id/MoIL-4 via the intraperitoneal route elicited higher titers of anti-idiotypic antibodies (79.0 \pm 25.6 μ g/ml) compared to that induced through the subcutaneous route (45.1 \pm 15.9 μ g/ml), while no significant difference of antibody titers was found in mice immunized with Id/MoIL-2 either intraperitoneally or subcutaneously. Animals immunized with a simple mixture of Id and recombinant murine IL-2 or IL-4 produced no anti-idiotypic response, indicating

-16-

that fusion of the cytokine molecule to tumor idiotype was required for enhanced immunogenicity. The carrier effects of murine IL-2 or murine IL-4 in the fusion protein in the immune responses was ruled out since
5 fusion proteins containing a similar size but biologically inert human GM-CSF or a peptide derived from the pre-S2 region of hepatitis B virus surface antigen # induced no anti-idiotypic antibodies. These results show that the fusion protein requires cytokine activity for
10 its immune-enhancing function. Compared with mice immunized with Id chemically conjugated to the strong carrier protein keyhole limpet hemocyanin (KLH) with adjuvant, titers of anti-idiotypic antibodies induced by Id/MoIL-4 and Id/MoIL-2 were about three-fold and five-
15 to seven-fold lower, respectively. The immune responses are specific because no reactivity occurred against other proteins such as KLH or 4C5 (an irrelevant mouse IgM). Fluorescent-activated cell sorting (FACS) analysis showed that the immune sera from mice vaccinated with Id/MoIL-2
20 or Id/MoIL-4 specifically recognized 38C13 tumor cells but not an immunoglobulin-negative variant.

Two weeks after the second immunization, mice were challenged with 38C13 tumor cells. Fig. 8A illustrates that mice vaccinated intraperitoneally with
25 Id/MoIL-2 or Id/MoIL-4 had a significantly prolonged survival time compared with mice receiving Id alone ($p < 0.01$ and $p < 0.01$). 50% of Id/MoIL-4 and 20% of Id/MoIL-2 immunized animals remained tumor free for greater than 120 days, whereas vaccination with Id
30 yielded only 10% long-term survivors. Mice immunized with Id along with recombinant IL-2 or IL-4 did not show any protection ($p > 0.7$ and $p > 0.2$) and all mice died of tumors before day 36. The positive control group receiving KLH-conjugated Id with adjuvant were well
35 protected and resulted in 60% survivors ($p < 0.01$) (Fig.

-17-

8A). Similar results were obtained from groups of mice immunized subcutaneously. As shown in Fig. 8B, mice immunized with Id/MoIL-2 and Id/MoIL-4 also induced protective immunity and resulted in 40% and 30% long-term survivors, respectively. Again, vaccination with a simple mixture of Id and IL-2 or IL-4 yielded no protection. The long-term survivors (>120 days after tumor challenge) were free of residual or dormant tumor cells by several criteria, including FACS analysis, in vitro culture and in vivo transfer of splenocytes. Tumors that did grow in the immunized animals were examined for surface idiotype expression and were found to be positive.

-18-

Claims

1. An immunocomplex consisting essentially of a B cell lymphoma tumor-associated antigen or an epitope-bearing portion thereof covalently bound to an immune-enhancing cytokine.
5
2. The immunocomplex of claim 1 wherein said tumor-associated antigen is an immunoglobulin.
10
3. The immunocomplex of claim 2 wherein said epitope-bearing portion is the idiotypic region of said immunoglobulin.
4. The immunocomplex of claim 1 wherein the immune-enhancing cytokine is selected from the group consisting of GM-CSF, IL-2 and IL-4.
15
5. The immunocomplex of claim 1 wherein said B cell lymphoma tumor-associated antigen or portion thereof and said immune-enhancing cytokine are coupled through a nonprotein linker.
20
6. The immunocomplex of claim 1 wherein said B cell lymphoma tumor-associated antigen or fragment thereof and said immune-enhancing cytokine are coupled directly or through a protein linker, said immunocomplex being a fusion protein.
25
7. A DNA encoding the immunocomplex of claim 6.
30
8. A recombinant expression system capable, when transformed into suitable host cells, of expressing a gene encoding the immunocomplex of claim 6, such
35

-19-

expression system comprising said encoding DNA operably linked to control sequences compatible with said host cell.

5 9. Recombinant host cells transformed with the expression system of claim 8.

10 10. A method to produce an immunocomplex, which immunocomplex comprises a fusion protein consisting essentially of a B cell lymphoma tumor-associated antigen or epitope-bearing fragment thereof coupled directly or through a protein linker to an immune-enhancing cytokine, which method comprises

15 (a) culturing the cells of claim 9 under conditions wherein the encoding DNA is expressed, and (b) recovering the immunocomplex from the culture.

20 11. A vaccine for protecting subjects against B cell lymphoma tumor proliferation, which vaccine comprises the immunocomplex of claim 1 in admixture with at least one pharmaceutically acceptable excipient.

25 12. Antibodies immunoreactive with the epitope-bearing portion of the immunocomplex of claim 1.

13. The antibodies of claim 12 which are monoclonal antibodies.

30 14. Antibodies immunospecific for the immunocomplex of claim 1.

15. The antibodies of claim 14 which are monoclonal antibodies.

35

-20-

16. A vaccine for conferring passive resistance to B cell lymphoma tumor proliferation, which vaccine comprises an effective amount of the antibodies of claim 12 in admixture with a pharmaceutically acceptable excipient.

17. A cytokine conjugate which consists essentially of an immune-enhancing cytokine coupled covalently to an additional molecular structure.

18. The conjugate of claim 17 wherein said cytokine is GM-CSF.

19. The conjugate of claim 17 wherein said cytokine is IL-2.

20. The conjugate of claim 17 wherein said cytokine is IL-4.

21. The conjugate of claim 17 which is a fusion protein.

22. A method to enhance immune response which method comprises contacting immunoresponsive cells with the conjugate of claim 17.

30

35




FIG.1B





FIG.1A



3 / 9




FIG.3

—○— NORMAL RAT IgG
 —●— RAT anti-GM-CSF
 —□— GOAT anti-HUMAN IgY
 —■— GOAT anti-HUMAN IgK




FIG.4




FIG.5




FIG.6A




FIG.6B




FIG.6C

7/9




FIG. 7A




FIG. 7B

SUBSTITUTE SHEET

8 / 9




FIG.7C






FIG.7D

SUBSTITUTE SHEET

9 / 9



SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/09895

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : Please See Extra Sheet.

US CL : 530/387.3; 424/85.8; 435/320, 252.3, 69.1, 91; 536/23.53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/387.3; 424/85.8; 435/320, 252.3, 69.1, 91; 536/23.53

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

SEARCH TERMS: IMMUNOCOMPLEX, IMMUNOCONJUGATE, CYTOKINE, ANTIBODY, FUSION PROTEIN

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| Y | JOURNAL OF IMMUNOLOGY, VOL. 138, NO.4, ISSUED 15 FEBRUARY 1987, M.S. KAMINSKI ET AL., "IDIOTYPE VACCINATION AGAINST MURINE B CELL LYMPHOMA. INHIBITION OF TUMOR IMMUNITY BY FREE IDIOTYPE PROTEIN", PAGES 1289-1296, SEE ENTIRE DOCUMENT. | 1-22 |
| Y | JOURNAL OF IMMUNOLOGY, VOLUME 139, NO.4, ISSUED 15 AUGUST 1987, P.J. MORRISSEY ET AL., "GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AUGMENTS THE PRIMARY ANTIBODY RESPONSE BY ENHANCING THE FUNCTION OF ANTIGEN PRESENTING CELLS", PAGES 1113-1119, SEE ENTIRE DOCUMENT. | 1-22 |

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "A" document defining the general state of the art which is not considered to be part of particular relevance | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "E" earlier document published on or after the international filing date | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Z" document member of the same patent family |
| "O" document referring to an oral disclosure, use, exhibition or other means | |
| "P" document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

07 December 1993

Date of mailing of the international search report

18 JAN 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

CHRIS EISENSCHENK

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/09895

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| Y | FEDERATION OF THE EUROPEAN BIOCHEMICAL SOCIETIES, VOL. 288, NO.1,2, ISSUED AUGUST 1991, S. HINUMA ET AL., "A NOVEL STRATEGY FOR CONVERTING RECOMBINANT VIRAL PROTEIN INTO HIGH IMMUNOGENIC ANTIGEN", PAGES 138-142, SEE ENTIRE DOCUMENT. | 1-22 |
| Y | MOL. BIOTHER., VOLUME 2, ISSUED JUNE 1990, "RECOMBINANT TARGETED PROTEINS FOR BIOTHERAPY", PAGES 67-73, SEE ESPECIALLY 69-70 "GENE FUSION PRODUCTS". | 1-22 |

INTERNATIONAL SEARCH REPORT

Inter. application No.

PCT/US93/09895

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (5):

A61K 37/00, 37/04; C07K 15/28; C12N 1/00, 15/13, 15/19, 15/10, 15/63